Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease

Pharmacology and Therapeutics

Volumn 114, Issue 3, 2007, Pages 327-344

  Sun, Faneng ^a   Kanthasamy, Arthi ^a   Anantharam, Vellareddy ^a   Kanthasamy, Anumantha G ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Synuclein; Dieldrin; Neurotoxicants; Neurotoxicity; Oxidative stess; Parkinson's disease; Proteasome; UPS

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; BORTEZOMIB; CURCUMIN; DIELDRIN; DOPAMINE; EPOXOMICIN; IRON; LACTACYSTIN; LACTONE; MANEB; MANGANESE; NEUROTOXIN; PARAQUAT; PROTEASOME; REPINOTAN; ROTENONE; UBIQUITIN;

AUTOOXIDATION; CELL CYCLE; CELL SURVIVAL; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GENE MUTATION; HUMAN; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; ENVIRONMENTAL POLLUTANTS; HUMANS; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 34249681825     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.04.001     Document Type: Review

References (212)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 1 (2000) 239-252
2. Amici M., Forti K., Nobili C., Lupidi G., Angeletti M., Fioretti E., et al. Effect of neurotoxic metal ions on the proteolytic activities of the 20S proteasome from bovine brain. J Biol Inorg Chem 7 7-8 (2002) 750-756
3. Andre C., Truong T.T., Robert J.F., and Guillaume Y.C. Effect of metals on herbicides-alpha-synuclein association: a possible factor in neurodegenerative disease studied by capillary electrophoresis. Electrophoresis 26 17 (2005) 3256-3264
4. Ardley H.C., and Robinson P.A. The role of ubiquitin-protein ligases in neurodegenerative disease. Neurodegener Dis 1 (2004) 71-87
5. Ardley H.C., Scott G.B., Rose S.A., Tan N.G., Markham A.F., and Robinson P.A. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell 14 11 (2003) 4541-4556
6. Ardley H.C., Scott G.B., Rose S.A., Tan N.G., and Robinson P.A. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 90 2 (2004) 379-391
7. Asanuma M., Miyazaki I., Diaz-Corrales F.J., and Ogawa N. Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 58 5 (2004) 221-233
8. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 5556 (2002) 865-868
9. Auluck P.K., Meulener M.C., and Bonini N.M. Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280 4 (2005) 2873-2878
10. Bandopadhyay R., Kingsbury A.E., Muqit M.M., Harvey K., Reid A.R., Kilford L., et al. Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol Dis 20 2 (2005) 401-411
11. Barzilai A., Melamed E., and Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?. Cell Mol Neurobiol 21 3 (2001) 215-235
12. Bennett M.C. The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105 3 (2005) 311-331
13. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79 2 (2001) 225-236
14. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 191 Suppl 1 (2005) S17-S27
15. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22 2 (2006) 404-420
16. Bilen J., and Bonini N.M. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 39 (2005) 153-171
17. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 3 (2005) 484-494
18. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60 2 (2006) 260-264
19. Bozzi Y., and Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci 29 3 (2006) 167-174
20. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., and Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823 1-2 (1999) 1-10
21. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22 20 (2002) 8797-8807
22. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19 10 (2005) 1377-1379
23. Casarejos M.J., Menendez J., Solano R.M., Rodriguez-Navarro J.A., Garcia de Yebenes J., and Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97 4 (2006) 934-946
24. Cauchi R.J., and van den Heuvel M. The fly as a model from neurodegenerative diseases: is it worth the jump?. Neurodegener Dis 3 6 (2006) 338-356
25. Chaudhuri K.R., Healy D.G., and Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 3 (2006) 235-245
26. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., and Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18 (2004) 1162-1164
27. Chen Q., Thorpe J., and Keller J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J Biol Chem 280 34 (2005) 30009-30017
28. Chen L., Thiruchelvam M.J., Madura K., and Richfield E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol Dis 23 1 (2006) 120-126
29. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279 13 (2004) 13256-13264
30. Chondrogianni N., and Gonos E.S. Proteasome dysfunction in mammalian aging: steps and factors involved. Exp Gerontol 40 (2005) 931-938
31. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7 10 (2001) 1144-1150
32. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 5675 (2004) 1328-1331
33. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 7097 (2006) 1162-1166
34. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., and Nussbaum R.L. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J Biol Chem 280 10 (2005) 9678-9690
35. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 5545 (2001) 1346-1349
36. Corrigan F.M., Wienburg C.L., Shore R.F., Daniel S.E., and Mann D. Organochlorine insecticides in substantia nigra in Parkinson's disease. J Toxicol Environ Health A 59 4 (2000) 229-234
37. Corti O., Hampe C., Koutnikova H., Darios F., Jacquier S., Prigent A., et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12 12 (2003) 1427-1437
38. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12 5 (2003) 517-526
39. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 6 (2003) 889-909
40. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 99 22 (2002) 14524-14529
41. Davies K.J. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83 3-4 (2001) 301-310
42. Di Monte D.A., Lavasani M., and Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology 23 4-5 (2002) 487-502
43. Di Rosa G., Puzzo D., Sant'Angelo A., Trinchese F., and Arancio O. Alpha-synuclein: between synaptic function and dysfunction. Histol Histopathol 18 4 (2003) 1257-1266
44. Ding Q., and Keller J.N. Proteasomes and proteasome inhibition in the central nervous system. Free Radic Biol Med 31 (2001) 574-584
45. Ding Q., and Keller J.N. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J Neurochem 77 4 (2001) 1010-1017
46. Ding Q., Dimayuga E., and Keller J.N. Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid Redox Signal 8 (2006) 163-172
47. Dinis-Oliveira R.J., Remiao F., Carmo H., Duarte J.A., Navarro A.S., Bastos M.L., et al. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology (2006)
48. Dong Z., Ferger B., Paterna J.C., Vogel D., Furler S., Osinde M., et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc Natl Acad Sci U S A 100 21 (2003) 12438-12443
49. Drolet R.E., Behrouz B., Lookingland K.J., and Goudreau J.L. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25 5 (2004) 761-769
50. Elkon H., Melamed E., and Offen D. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol 21 6 (2001) 771-781
51. Elkon H., Melamed E., and Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J Mol Neurosci 24 3 (2004) 387-400
52. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 6776 (2000) 394-398
53. Fenteany G., Standaert R.F., Reichard G.A., Corey E.J., and Schreiber S.L. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci U S A 91 8 (1994) 3358-3362
54. Fernagut P.O., and Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17 2 (2004) 123-130
55. Fleming L., Mann J.B., Bean J., Briggle T., and Sanchez-Ramos J.R. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 36 1 (1994) 100-103
56. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 102 9 (2005) 3413-3418
57. Furukawa K., Matsuzaki-Kobayashi M., Hasegawa T., Kikuchi A., Sugeno N., Itoyama Y., et al. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 97 4 (2006) 1071-1077
58. Ghee M., Fournier A., and Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 75 5 (2000) 2221-2224
59. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82 2 (2002) 373-428
60. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278 44 (2003) 43628-43635
61. Golts N., Snyder H., Frasier M., Theisler C., Choi P., and Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 277 18 (2002) 16116-16123
62. + increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 935 1-2 (2002) 32-39
63. Gray D.A., Tsirigotis M., and Woulfe J. Ubiquitin, proteasomes, and the aging brain. Sci Aging Knowledge Environ (2003) RE6
64. Groll M., and Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695 1-3 (2004) 33-44
65. Halliwell B. Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration. Antioxid Redox Signal 8 (2006) 2007-2019
66. Hartmann-Petersen R., and Gordon C. Protein degradation: recognition of ubiquitinylated substrates. Curr Biol 14 18 (2004) R754-R756
67. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10 4 (1999) 717-721
68. Hayashita-Kinoh H., Yamada M., Yokota T., Mizuno Y., and Mochizuki H. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 341 4 (2006) 1088-1095
69. Haywood A.F., and Staveley B.E. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci 5 14 (2004)
70. Haywood A.F., and Staveley B.E. Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. Genome 49 5 (2006) 505-510
71. Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y., and Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. J Neurochem 89 6 (2004) 1490-1497
72. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86 5 (2003) 1297-1307
73. Holtz W.A., and O'Malley K.L. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278 (2003) 19367-19377
74. Huynh D.P., Scoles D.R., Nguyen D., and Pulst S.M. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet 12 20 (2003) 2587-2597
75. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., and Takahashi R. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 10 (2002) 55-67
76. Ishii T., Sakurai T., Usami H., and Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 44 42 (2005) 13893-13901
77. Jain H., Wood N.W., and Healy D.G. Molecular genetic pathways in Parkinson's disease: a review. Clin Sci 109 (2005) 355-364
78. Jiang H., Ren Y., Zhao J., and Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13 16 (2004) 1745-1754
79. Jimenez del Rio M., and Velez-Pardo C. Molecular mechanism of monoamine toxicity in Parkinson's disease: hypothetical cell death model. Med Hypotheses 54 2 (2000) 269-274
80. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 279 15 (2004) 15240-15247
81. Kanthasamy A.G., and Kaul S. Animal models of Parkinson's disease. In: Tatlisumak T., and Fisher M. (Eds). Handbook of Experimental Neurology: Methods and Techniques in Animal Research (2006), Cambridge University Press, New York, NY 411-437
82. Kanthasamy A.G., Kitazawa M., Kanthasamy A., and Anantharam V. Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox Signal 5 5 (2003) 609-620
83. Kanthasamy A.G., Kitazawa M., Kanthasamy A., and Anantharam V. Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. Neurotoxicology 26 4 (2005) 701-719
84. +-induced apoptotic cell death. Brain Res Mol Brain Res 139 1 (2005) 137-152
85. Kaur D., and Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res Rev 3 3 (2004) 327-343
86. Keller J.N., Huang F.F., Dimayuga E.R., and Maragos W.F. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 29 10 (2000) 1037-1042
87. Khan N.L., Scherfler C., Graham E., Bhatia K.P., Quinn N., Lees A.J., et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64 1 (2005) 134-136
88. Kikuchi S., Shinpo K., Tsuji S., Takeuchi M., Yamagishi S., Makita Z., et al. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res 964 2 (2003) 228-236
89. Kirkpatrick D.S., Denison C., and Gygi S.P. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat Cell Biol 7 8 (2005) 750-757
90. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8 8 (2001) 739-758
91. Kitazawa M., Anantharam V., and Kanthasamy A.G. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic Biol Med 31 11 (2001) 1473-1485
92. Kitazawa M., Anantharam V., and Kanthasamy A.G. Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase Cdelta in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration. Neuroscience 119 4 (2003) 945-964
93. Klein R.L., Dayton R.D., Henderson K.M., and Petrucelli L. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model. Neurosci Lett 401 1-2 (2006) 130-135
94. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21 3 (2006) 541-548
95. Ko H.S., von Coelln R., Sriram S.R., Kim S.W., Chung K.K., Pletnikova O., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25 35 (2005) 7968-7978
96. Ko H.S., Kim S.W., Sriram S.R., Dawson V.L., and Dawson T.M. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281 24 (2006) 16193-16196
97. Koguchi Y., Kohno J., Nishio M., Takahashi K., Okuda T., Ohnuki T., et al. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot (Tokyo) 53 2 (2000) 105-109
98. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell III J., Terpstra B.T., et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 60 2 (2006) 264-268
99. Lai B.C., Marion S.A., Teschke K., and Tsui J.K. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord 8 5 (2002) 297-309
100. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 15 (1998) 1044-1053
101. Langston J.W., and Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 11 1 Suppl (1984) 160-165
102. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11 11 (2005) 1214-1221
103. Lee C.S., Tee L.Y., Warmke T., Vinjamoori A., Cai A., Fagan A.M., et al. A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 91 4 (2004) 996-1006
104. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 6701 (1998) 451-452
105. Lev N., Melamed E., and Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett 399 1-2 (2006) 27-32
106. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., and Fink A.L. Dopamine and l-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18 9 (2004) 962-964
107. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279 13 (2004) 12924-12934
108. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury Jr. P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 2 (2002) 209-218
109. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 101 50 (2004) 17510-17515
110. Lotharius J., and Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11 20 (2002) 2395-2407
111. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 277 41 (2002) 38884-38894
112. Magerkurth C., Schnitzer R., and Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 15 2 (2005) 76-82
113. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277 3 (2002) 1641-1644
114. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., and Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23 8 (2003) 3095-3099
115. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60 2 (2006) 256-260
116. Maries E., Dass B., Collier T.J., Kordower J.H., and Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 4 9 (2003) 727-738
117. McCormack A.L., and Di Monte D.A. Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem 85 1 (2003) 82-86
118. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10 2 (2002) 119-127
119. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 60 2 (2006) 243-247
120. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., and Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326 3 (2002) 155-158
121. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. NeuroReport 13 11 (2002) 1437-1441
122. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81 2 (2002) 301-306
123. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 1 (2003) 38-46
124. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 1 (2004) 149-162
125. Meulener M.C., Xu K., Thomson L., Ischiropoulos H., and Bonini N.M. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci U S A 103 33 (2006) 12517-12522
126. Miwa H., Kubo T., Suzuki A., Nishi K., and Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett 380 1-2 (2005) 93-98
127. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 (2005) 57-87
128. Myung J., Kim K.B., and Crews C.M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21 4 (2001) 245-273
129. Nam S., Smith D.M., and Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276 16 (2001) 13322-13330
130. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304 1 (2003) 176-183
131. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280 22 (2005) 21212-21219
132. Okada K., Wangpoengtrakul C., Osawa T., Toyokuni S., Tanaka K., and Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274 34 (1999) 23787-23793
133. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann NY Acad Sci 1012 (2004) 209-223
134. Oluwatosin-Chigbu Y., Robbins A., Scott C.W., Arriza J.L., Reid J.D., and Zysk J.R. Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells. Biochem Biophys Res Commun 309 3 (2003) 679-684
135. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., and Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20 16 (2000) 6048-6054
136. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 18 (2004) 18614-18622
137. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 7097 (2006) 1157-1161
138. Passmore L.A., and Barford D. Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem J 379 Pt 3 (2004) 513-525
139. Pawlyk A.C., Giasson B.I., Sampathu D.M., Perez F.A., Lim K.L., Dawson V.L., et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 278 48 (2003) 48120-48128
140. Peng J., Schwartz D., Elias J.E., Thoreen C.C., Cheng D., Marsischky G., et al. A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 21 8 (2003) 921-926
141. Perez F.A., and Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 102 6 (2005) 2174-2179
142. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 8 (2002) 3090-3099
143. Perez F.A., Curtis W.R., and Palmiter R.D. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 6 71 (2005)
144. Periquet M., Corti O., Jacquier S., and Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J Neurochem 95 5 (2005) 1259-1276
145. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 6 (2002) 1007-1019
146. Pickart C.M., and Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695 1-3 (2004) 55-72
147. Pickart C.M., and Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 8 6 (2004) 610-616
148. Pierson J., Svenningsson P., Caprioli R.M., and Andren P.E. Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats. J. Proteome Res 4 2 (2005) 223-226
149. Pifl C., Khorchide M., Kattinger A., Reither H., Hardy J., and Hornykiewicz O. alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter. Neurosci Lett 354 1 (2004) 34-37
150. Purisai M.G., McCormack A.L., Langston W.J., Johnston L.C., and Di Monte D.A. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20 3 (2005) 898-906
151. Reaney S.H., Johnston L.C., Langston W.J., and Di Monte D.A. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol (2006)
152. Rechsteiner M., and Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15 1 (2005) 27-33
153. Ren Y., Zhao J., and Feng J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23 8 (2003) 3316-3324
154. Rideout H.J., and Stefanis L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol Cell Neurosci 21 2 (2002) 223-238
155. Rideout H.J., Dietrich P., Wang Q., Dauer W.T., and Stefanis L. alpha-Synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. J Biol Chem 279 45 (2004) 46915-46920
156. Rideout H.J., Lang-Rollin I.C., Savalle M., and Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem 93 5 (2005) 1304-1313
157. Ryu E.J., Harding H.P., Angelastro J.M., Vitolo O.V., Ron D., and Greene L.A. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 22 (2002) 10690-10698
158. Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S., Yamada S., et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep 4 3 (2003) 301-306
159. Sanchez-Ramos J., Facca A., Basit A., and Song S. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol 150 2 (1998) 263-271
160. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., et al. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279 11 (2004) 10710-10719
161. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., and King R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60 2 (2006) 253-255
162. Shamoto-Nagai M., Maruyama W., Kato Y., Isobe K., Tanaka M., Naoi M., et al. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74 4 (2003) 589-597
163. Shamoto-Nagai M., Maruyama W., Yi H., Akao Y., Tribl F., Gerlach M., et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm 113 5 (2006) 633-644
164. Shen J., and Cookson M.R. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43 3 (2004) 301-304
165. Shimizu K., Ohtaki K., Matsubara K., Aoyama K., Uezono T., Saito O., et al. Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 906 1-2 (2001) 135-142
166. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 3 (2000) 302-305
167. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 5528 (2001) 263-269
168. Sidhu A., Wersinger C., Moussa C.E., and Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann NY Acad Sci 1035 (2004) 250-270
169. Sitia R., and Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 426 (2003) 891-894
170. Smith W.W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14 (2005) 3801-3811
171. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., and Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 278 14 (2003) 11753-11759
172. Song D.D., Shults C.W., Sisk A., Rockenstein E., and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 186 2 (2004) 158-172
173. Stevens K.L., Riopelle R.J., and Wong R.Y. Repin, a sesquiterpene lactone from Acroptilon repens possessing exceptional biological activity. J Nat Prod 53 1 (1990) 218-221
174. Sun L., and Chen Z.J. The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 16 2 (2004) 119-126
175. Sun F., Anantharam V., Latchoumycandane C., Kanthasamy A., and Kanthasamy A.G. Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J Pharmacol Exp Ther 315 1 (2005) 69-79
176. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A., and Kanthasamy A.G. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 27 5 (2006) 807-815
177. Tam S., Barry D.P., Beaman L., and Beaman B.L. Neuroinvasive Nocardia asteroides GUH-2 induces apoptosis in the substantia nigra in vivo and dopaminergic cells in vitro. Exp Neurol 177 2 (2002) 453-460
178. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10 9 (2001) 919-926
179. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., and Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279 6 (2004) 4625-4631
180. Tanner C.M. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 91 (2003) 133-142
181. Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., and Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19 4 (2004) 845-854
182. Tsukamoto S., and Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 13 7 (2006) 745-754
183. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276 47 (2001) 44284-44296
184. Uversky V.N., Li J., and Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 500 3 (2001) 105-108
185. Ved R., Saha S., Westlund B., Perier C., Burnam L., Sluder A., et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280 52 (2005) 42655-42668
186. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther (2006)
187. Volles M.J., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41 14 (2002) 4595-4602
188. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 26 (2001) 7812-7819
189. von Bohlen und Halbach O., Schober A., and Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 73 3 (2004) 151-177
190. Voorhees P.M., and Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46 (2006) 189-213
191. Wang C., Ko H.S., Thomas B., Tsang F., Chew K.C., Tay S.P., et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14 24 (2005) 3885-3897
192. Wang X.F., Li S., Chou A.P., and Bronstein J.M. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol Dis 23 1 (2006) 198-205
193. Warner T.T., and Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S16-S23 (discussion S23--15)
194. Wersinger C., and Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340 3 (2003) 189-192
195. Whitworth A.J., Wes P.D., and Pallanck L.J. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov Today 11 3-4 (2006) 119-126
196. Widmer R., Ziaja I., and Grune T. Protein oxidation and degradation during aging: role in skin aging and neurodegeneration. Free Radic Res 40 (2006) 1259-1268
197. Wolozin B., and Golts N. Iron and Parkinson's disease. Neuroscientist 8 1 (2002) 22-32
198. Yamada M., Mizuno Y., and Mochizuki H. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 16 2 (2005) 262-270
199. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 6 (2003) 911-924
200. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 7 (2005) 5892-5901
201. Yang Y., Gehrke S., Haque M.E., Imai Y., Kosek J., Yang L., et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A 102 38 (2005) 13670-13675
202. Yao D., Gu Z., Nakamura T., Shi Z.Q., Ma Y., Gaston B., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 101 29 (2004) 10810-10814
203. Yavich L., Tanila H., Vepsalainen S., and Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 24 49 (2004) 11165-11170
204. Yew E.H., Cheung N.S., Choy M.S., Qi R.Z., Lee A.Y., Peng Z.F., et al. Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem 94 (2005) 943-956
205. Yoshimoto Y., Nakaso K., and Nakashima K. l-Dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett 579 5 (2005) 1197-1202
206. Zafar K.S., Siegel D., and Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70 3 (2006) 1079-1086
207. Zeevalk G.D., and Bernard L.P. Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures. Antioxid Redox Signal 7 5-6 (2005) 662-672
208. Zeng B.Y., Medhurst A.D., Jackson M., Rose S., and Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age. Mech Ageing Dev 126 (2005) 760-766
209. Zeng B.Y., Iravani M.M., Lin S.T., Irifune M., Kuoppamaki M., Al-Barghouthy G., et al. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci 23 7 (2006) 1766-1774
210. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 97 24 (2000) 13354-13359
211. Zhang X., Xie W., Qu S., Pan T., Wang X., and Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333 2 (2005) 544-549
212. Zhou Y., Shie F.S., Piccardo P., Montine T.J., and Zhang J. Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: relevance to Parkinson's disease. Neuroscience 128 2 (2004) 281-291